Novaccel Therapeutics

NovAccel is a Japanese medical-isotope startup developing compact superconducting accelerator technology to produce actinium-225, a key isotope used in targeted alpha therapy for cancer. The company is focused on building a stable, scalable supply chain for high-purity Ac-225, addressing a major bottleneck in radiopharmaceutical development and clinical adoption. Its core platform, RiSA, is an ultra-compact superconducting electron accelerator intended to support domestic and broader commercial production of medical radioisotopes. NovAccel also conducts collaborative and contract R&D based on its accelerator expertise. The company was founded in 2024 and is advancing toward initial Ac-225 production and larger-scale operations.